Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezeprogind - AlzProtect

Next Previous
Drug Profile

Ezeprogind - AlzProtect

Alternative Names: AZP 2006

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AlzProtect; INSERM; University of Lille 2
  • Developer AlzProtect
  • Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Progranulin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Progressive supranuclear palsy
  • Phase I Alzheimer's disease
  • Preclinical Parkinson's disease

Most Recent Events

  • 13 Mar 2024 Alzprotect plans the pivotal phase-IIb/III PROMISE-PSP trial for Progressive supranuclear palsy in Europe and the US in late 2024
  • 28 Aug 2023 3816685: Updated KDM, added AE/PK data and clinical HE; added OLE trial initiation HE; updated planned trial phase in FET
  • 16 Jul 2023 Pharmacodynamics data from a preclinical studies in Progressive Supranuclear Palsy and Alzheimer’s Disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top